Hans-Peter Kiem study is first to show patients' own gene-modified blood stem cells can protect bone marrow from chemotherapy toxicity
May 14, 2012
| By Dean Forbes
For the first time, Fred Hutchinson Cancer Research Center scientists have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of chemotherapy. Initial results of the ongoing, small clinical trial of three patients with glioblastoma showed that two patients survived longer than predicted if they had not been given the transplants, and a third patient remains alive with no disease progression almost three years after treatment.
Hans-Peter Kiem and colleagues find chemo-resistant genes may enable safer, more effective treatment for brain cancer patients
May 23, 2011
| By Dean Forbes
Chemotherapy kills cancer cells, but its toxic effects on normal cells such as bone marrow and blood cells limits its use. Fred Hutchinson Cancer Research Center researchers have found a possible approach to reduce this toxicity: modify the bone marrow cells with a gene that makes them resistant to chemotherapy.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.